From the Bench, AACR Annual Meeting 2026: Innovative Tools Uncover New Insights Into Cancer
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
Tag: Drug resistance
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
At a recent AACR Special Conference, experts discussed emerging therapeutic options to overcome resistance to Bacillus Calmette-Guérin (BCG).
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Researchers are exploring new options for kidney cancer treatments.
Immune checkpoint inhibition is a form of cancer immunotherapy that works by releasing the “brakes” on the immune system, thereby increasing...
In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to...
Genomic analysis of estrogen receptor (ER)-positive metastatic breast cancer samples that had become resistant to therapies revealed multiple alterations...
This post explores the challenges we face with anti-EGFR monoclonal antibody therapies and new strategies researchers have developed to...
Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung...